General description
A selective, cell-permeable, irreversible, slow, tight-binding inhibitor of inducible nitric oxide synthase (iNOS; Kd = 7 nM). Suitable for use in both in vitro and in vivo systems. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
A selective, irreversible, slow, tight binding inhibitor of inducible nitric oxide synthase (iNOS, Kd = 7 nM) both in vitro and in vivo. Has a protective effect against cerebral ischemia by reducing ischemic lesion volumes. Exhibits greater than 5000- and 200-fold potency against human iNOS relative to eNOS and nNOS, respectively, and greater than 1000-fold potency against rat iNOS relative to eNOS.
Biochem/physiol Actions
Cell permeable: yes
Kd = 7 nM against inducible nitric oxide synthase (iNOS)
Primary Target
iNOS
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable up to 3 months at -20°C.
Other Notes
Parmentier, S., et al. 1999. Br. J. Pharmacol.127, 546.
Cardenas, A., et al. 1998. Eur. J. Pharmacol. 354, 161.
Parrino, P.E., et al. 1998. Ann. Thorac. Surg. 66, 733.
Garvey, E.P., et al. 1997. J. Biol. Chem. 272, 4959.
Laszlo, F., and Whittle, B.J. 1997. Eur. J. Pharmacol. 334, 99.
Thomsen, L.L., et al. 1997. Cancer Res. 57, 3300.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 41113708
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 100050-5MG
